Company / R&D per Share
UroGen Pharma Ltd. R&D per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.59
FY2025
5-year range
$1.40 / $2.29
FY2021-FY2025
Trend
+13.2%
vs FY2024
Sector context
#120 of 208
Health Care
What the data says
At $1.59, UroGen Pharma Ltd.'s r&d per share ranks #120 of 208 in the Health Care sector. R&D per Share has fluctuated over the past 9 years, ranging from $1.15 in FY2019 to $2.69 in FY2018.
Based on SEC 10-K filings.
1.59 in FY2025 with a 5-year CAGR of -7.5%.
Declined from $2.29 to $1.59 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -9.2%
- 5-Year CAGR
- -7.5%
- 10-Year CAGR
- -
Sector benchmark
#120 of 208 in Health CareTop 58% of 208This company $1.59 Sector average $28.82
▼
-94.5% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 13.2% year-over-year.
- Ranks #120 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2018.
- Lowest r&d per share in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.59 | +13.2% |
| FY2024 | $1.40 | -38.6% |
| FY2023 | $2.29 | +7.8% |
| FY2022 | $2.12 | -1.3% |
| FY2021 | $2.15 | -8.3% |
| FY2020 | $2.34 | +103.3% |
| FY2019 | $1.15 | -57.1% |
| FY2018 | $2.69 | +39.6% |
| FY2017 | $1.92 | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026